虽然 [18F]FET PET 在神经胶质瘤成像中发挥着补充作用，但鉴于分子神经病理学的不断发展，需要更全面地了解它，以在手术前改善神经胶质瘤的表征。因此，我们研究了术前双时间点 [18F]FET PET 与下一代测序 (NGS) 数据相关的成人型弥漫性胶质瘤 (ADG) 患者的效用。原发性神经胶质瘤是在 2021 年 6 月至 2024 年 1 月期间前瞻性招募的。他们在注射 [18F]FET 后 20 分钟（早期）和 80 分钟（延迟）接受术前双时间点静态 PET/CT。从每个求和图像中评估肿瘤最热病变（SUVmax）和最热病变与正常脑比率（TBRmax）的半定量参数。此外，还计算了两幅图像之间SUVmax和TBRmax的百分比变化（△）。胶质瘤的组织病理学根据2021年WHO分类和NGS数据确定。本研究调查了76名患者的十几个基因，其中51名患有异柠檬酸脱氢酶（IDH）野生型胶质母细胞瘤，13名患有IDH突变型星形细胞瘤，12名患有异柠檬酸脱氢酶（IDH）野生型胶质母细胞瘤。 IDH 突变型少突胶质细胞瘤。每个肿瘤都热衷于 [18F]FET，其 TBRmax 超过 1.6。 CDKN2A/B缺失的患者的SUVmax值显着升高（5.7±±1.6 vs. 4.7±±1.3，p=±0.004；5.0±±1.4 vs. 4.4±±1.2，p=±0.026）和TBRmax（6.5±±） 1.8 vs. 5.1 ± 1.7 ，p = 0.001；5.3 ± 1.5 vs. 4.3 ± 1.3，p = 0.004）在两次扫描中均高于没有 CDKN2A/B 缺失的患者，即使在调整了年龄、MRI 增强、肿瘤分级和病理类型之后也是如此。此外，即使在调整了年龄、MRI 增强、肿瘤分级和病理类型后，PIK3CA 突变患者 (16.2±±11.8 vs. 6.7±±11.6，p=±0.007) 的 ΔSUVmax 显着高于无 PIK3CA 突变的患者。在这项前瞻性研究中，我们对 ADG 患者的十几个基因进行了调查，我们发现 CDKN2A/B 缺失和 PIK3CA 突变状态可以通过术前双时间点 [18F]FET PET/CT 来区分。© 2024。 s)，获得 Springer-Verlag GmbH 德国（施普林格自然的一部分）的独家许可。

While [18F]FET PET plays a complementary role in glioma imaging, it needs to be more comprehensively understood for improved characterization of glioma prior to surgery given the evolving landscape of molecular neuropathology. Thus, we investigated the utility of pre-operative dual-time-point [18F]FET PET in correlation with next-generation sequencing (NGS) data in patients with adult-type diffuse glioma (ADG).Adult patients who were suspected to have primary glioma were prospectively recruited between June 2021 and January 2024. They underwent pre-operative dual-time-point static PET/CT at 20 min (early) and 80 min (delay) after [18F]FET injection. Semi-quantitative parameters of the hottest lesion (SUVmax) of tumour and the hottest lesion-to-normal brain ratio (TBRmax) were assessed from each summed image. Furthermore, the percentage changes (△) of SUVmax and TBRmax between two images were calculated. Histopathology of glioma was determined according to the 2021 WHO classification and NGS data.This study investigated a dozen genes in 76 patients, of whom 51 had isocitrate dehydrogenase (IDH)-wild-type glioblastoma, 13 had IDH-mutant astrocytoma, and 12 had IDH-mutant oligodendroglioma. Every tumour was [18F]FET-avid having TBRmax more than 1.6. Patients with CDKN2A/B loss had significantly higher values of SUVmax (5.7 ± 1.6 vs. 4.7 ± 1.3, p = 0.004; 5.0 ± 1.4 vs. 4.4 ± 1.2, p = 0.026) and TBRmax (6.5 ± 1.8 vs. 5.1 ± 1.7, p = 0.001; 5.3 ± 1.5 vs. 4.3 ± 1.3, p = 0.004) in both scans than patients without CDKN2A/B loss, even after adjustment for age, MRI enhancement, tumor grade and type of pathology. Furthermore, patients with PIK3CA mutation (16.2 ± 11.8 vs. 6.7 ± 11.6, p = 0.007) had significantly higher △SUVmax than patients without PIK3CA mutation, even after adjustment for age, MRI enhancement, tumor grade, and type of pathology.Among the dozen genes investigated in this prospective study in patients with ADG, we found out that CDKN2A/B loss and PIK3CA mutation status could be differentiated by pre-operative dual-time-point [18F]FET PET/CT.© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.